Should Beta Bionics Inc (NASDAQ: BBNX) Revive After A -86.31% Drop From Highs?

During the last session, Beta Bionics Inc (NASDAQ:BBNX)’s traded shares were 1.16 million. At the end of the trading day, the stock’s price was $13.15, reflecting an intraday loss of -13.60% or -$2.07. The 52-week high for the BBNX share is $24.50, that puts it down -86.31 from that peak though still a striking -3.73% loss since the share price plummeted to a 52-week low of $13.64. The company’s market capitalization is $569.79M, and the average intraday trading volume over the past 10 days was 0.68 million shares, and the average trade volume was 635.10K shares over the past three months.

Beta Bionics Inc (NASDAQ:BBNX) trade information

Beta Bionics Inc (BBNX) registered a -13.60% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -13.60% in intraday trading to $13.15, hitting a weekly high. The stock’s 5-day price performance is -16.72%, and it has moved by -31.40% in 30 days. The short interest in Beta Bionics Inc (NASDAQ:BBNX) is 1.21 million shares and it means that shorts have 3.43 day(s) to cover.

Beta Bionics Inc (BBNX) estimates and forecasts

In the rating firms’ projections, revenue will increase 26.77% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.82M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 19.24M by the end of current fiscal year.

While earnings are projected to return 78.87% in 2025, the next five years will return 38.50% per annum.

BBNX Dividends

Beta Bionics Inc is due to release its next quarterly earnings on 2025-Mar-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Beta Bionics Inc (NASDAQ:BBNX)’s Major holders

Beta Bionics Inc insiders own 7.52% of total outstanding shares while institutional holders control 57.53%, with the float percentage being 62.21%.